T1	intervention 21 47	lymphedema self-management
T2	condition 69 101	breast cancer-related lymphedema
T3	No-of-participants 329 338	Sixty-one
T4	eligibility 339 361	breast cancer patients
T5	control 728 742	control groups
T6	outcome-Measure 852 933	"DASH", "Measurement of Upper Extremity", " EORTC QLQ-30 and BR-23 questionnaire"
T7	outcome 1111 1133	lymphedema development
T8	control-value 1178 1183	61.2%
T9	outcome 1395 1410	quality of life
